Dutch biotech company VarmX has announced the publication in Nature Communications of a study on a safe and effective reversal agent for prevention and treatment of bleeding in patients taking factor Xa oral anticoagulants.
VarmX's lead compound PseudoXa was inspired by a snake venom protein.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze